European collaborative evaluation of the enzygnost HBsAg 6.0 assay: Performance on hepatitis B virus surface antigen variants

Journal of Medical Virology

Volumn 83, Issue 1, 2011, Pages 95-100

  Avellón, Ana ^a   Echevarría, José M ^a   Weber, Bernard ^b   Weik, Michael ^c   Schobel, Uwe ^c   Willems, Wulf R ^d   Gerlich, Wolfram H ^d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Laboratoires Réunis Junglister   (Germany)

^c Siemens Healthcare Diagnostics Products GmbH   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

HBsAg mutants; HBsAg testing; Hepatitis B; Hepatitis B virus surface antigen; Hepatitis B virus variants

Indexed keywords

AMINO ACID; HEPATITIS B SURFACE ANTIGEN;

AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; ENZYME MODIFICATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MUTANT; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SUPERNATANT; VIRUS DETECTION; VIRUS RECOMBINANT;

AMINO ACID SUBSTITUTION; ANTIGENS, VIRAL; EUROPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; IMMUNOASSAY; INTERNATIONAL COOPERATION; MUTATION, MISSENSE; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HEPATITIS B VIRUS;

EID: 78649594124     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21943     Document Type: Article

References (14)

1. Avellón A, Echevarría JM. 2006. Frequency of hepatitis B virus "a" determinant variants in unselected Spanish chronic carriers. J Med Virol 78: 24-36.
2. Coleman PF, Chen YC, Mushahwar IK. 1999. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 59: 19-24.
3. Echevarría JM, Avellón A. 2006. Hepatitis B virus genetic diversity. J Med Virol 78: S36-S42.
4. Echevarría JM, Avellón A. 2008. Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the VITROS(R) HBsAg assay. J Med Virol 80: 598-602.
5. Gerlich WH. 2004. Diagnostic problems caused by HBsAg mutants-A consensus report of an expert meeting. Intervirology 47: 310-313.
6. La'ulu SL, Roberts WL. 2006. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 125: 748-751.
7. Louisirirotchanakul S, Kanoksinsombat C, O'Charoen R, Fongsatikul L, Puapairoj C, Lulitanond V, Appassakij H, Promwong C, Wasi C. 2006. HBsAg diagnostic kits in the detection of hepatitis B virus mutation within "a" determinant. Viral Immunol 19: 108-114.
8. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, Dussaix E, Lapèrche S, Roque-Afonso AM. 2006. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 44: 2321-2326.
9. Mühlbacher A, Weber B, Burgisser P, Eiras A, Cabrera J, Louisirirotchanakul S, Tiller FW, Kim HS, Helden JV, Bossi V, Echevarría JM. 2008. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 197: 55-64.
10. Scheiblauer H, Soboll H, Nick S. 2006. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78: S66-S70.
11. Scheiblauer H, El-Nageh M, Díaz S, Nick S, Zeichhardt H, Grunert H-P, Prince A. 2010. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang 98: 403-414.
12. Weber B. 2006. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 78: S59-S65.
13. Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. 2006. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg ultra. J Virol Methods 135: 109-117.
14. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. 2003. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102: 1930.